GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Earnings per Share (Diluted)

Anixa Biosciences (Anixa Biosciences) Earnings per Share (Diluted) : $-0.37 (TTM As of Apr. 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Earnings per Share (Diluted)?

Anixa Biosciences's Earnings per Share (Diluted) for the three months ended in Apr. 2024 was $-0.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2024 was $-0.37.

Anixa Biosciences's EPS (Basic) for the three months ended in Apr. 2024 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2024 was $-0.37.

Anixa Biosciences's EPS without NRI for the three months ended in Apr. 2024 was $-0.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2024 was $-0.37.

During the past 3 years, the average EPS without NRIGrowth Rate was 10.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.10% per year.

During the past 13 years, Anixa Biosciences's highest 3-Year average EPS without NRI Growth Rate was 43.20% per year. The lowest was -73.10% per year. And the median was 4.60% per year.


Anixa Biosciences Earnings per Share (Diluted) Historical Data

The historical data trend for Anixa Biosciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Earnings per Share (Diluted) Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.59 -0.45 -0.45 -0.45 -0.32

Anixa Biosciences Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.08 -0.09 -0.10 -0.10

Competitive Comparison of Anixa Biosciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Anixa Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's PE Ratio falls into.



Anixa Biosciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Anixa Biosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Oct. 2023 is calculated as

Diluted Earnings Per Share (A: Oct. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.811-0)/30.980
=-0.32

Anixa Biosciences's Earnings Per Share (Diluted) for the quarter that ended in Apr. 2024 is calculated as

Diluted Earnings Per Share (Q: Apr. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-3.139-0)/31.914
=-0.10

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Anixa Biosciences  (NAS:ANIX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Anixa Biosciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747